Precision BioSciences, Inc. (DTIL)
DTIL moved a median of -0.39% 30 minutes after news, and -0.41% by the close. How DTIL actually reacts to news — the realized, point-in-time move the market made, measured across 394 labeled events over the last three years with zero look-ahead.
DTIL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 379 |
| 30-min | -0.39% | 43% | 393 |
| 60-min | -0.49% | 40% | 393 |
| to close | -0.41% | 44% | 394 |
| Middle 50% of DTIL reactions | -2.26% to +0.97% |
|---|---|
| Median reaction (30-min) | -0.39% |
| Measured reactions | 394 |
Half of all Precision BioSciences, Inc. news events land between -2.26% and +0.97% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when DTIL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DTIL's baseline. Nothing else.
Recent DTIL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 | Press release | Business Wire | +0.16% | +2.88% | |
| iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026 | Press release | Business Wire | -1.76% | -1.64% | |
| Form 8-K PRECISION BIOSCIENCES For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | -1.93% | -4.20% | |
| Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study | Press release | Business Wire | -1.93% | -4.20% | |
| iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium | Press release | Business Wire | +1.05% | +1.40% | |
| Form S-8 PRECISION BIOSCIENCES | SEC filing · Form S-8 | SEC EDGAR | +1.07% | +0.27% | |
| Form 10-Q PRECISION BIOSCIENCES For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.50% | +6.00% | |
| Form 8-K PRECISION BIOSCIENCES For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +6.50% | +6.00% | |
| Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | +6.50% | +6.00% | |
| Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | Business Wire | -1.41% | -1.27% | |
| Form 8-K PRECISION BIOSCIENCES For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | -0.55% | |
| Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones | Press release | Business Wire | -0.21% | -0.55% | |
| Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.00% | -4.47% | |
| Form 8-K PRECISION BIOSCIENCES For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | -1.00% | |
| Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors | Press release | Business Wire | +2.33% | +8.79% | |
| Form 8-K PRECISION BIOSCIENCES For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.17% | |
| Form 8-K PRECISION BIOSCIENCES For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -9.88% | -5.13% | |
| Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 | Press release | Business Wire | -9.88% | -5.13% | |
| Form 8-K PRECISION BIOSCIENCES For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -9.88% | -5.13% | |
| Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 | Press release | Business Wire | -2.18% | +0.70% | |
| iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial | Press release | Business Wire | +2.74% | -4.79% | |
| Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting | Press release | Business Wire | +0.72% | -2.99% | |
| iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting | Press release | Business Wire | +0.41% | +3.09% | |
| Form 10-Q PRECISION BIOSCIENCES For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.71% | +5.38% | |
| Form 8-K PRECISION BIOSCIENCES For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | +5.38% | |
| Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | +0.71% | +5.38% | |
| Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 | Press release | Business Wire | +1.38% | +3.47% | |
| Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study | Press release | Business Wire | +0.28% | -2.82% | |
| iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings | Press release | Business Wire | +1.43% | +1.43% | |
| Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting | Press release | Business Wire | +1.43% | +1.43% | |
| Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.91% | -4.09% | |
| Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Press release | Business Wire | +1.20% | +5.75% | |
| Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries | Press release | Business Wire | -0.82% | +4.93% | |
| Form ARS PRECISION BIOSCIENCES For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.25% | -6.70% | |
| Form DEF 14A PRECISION BIOSCIENCES For: May 21 | SEC filing · Form DEF | SEC EDGAR | +1.25% | -6.70% | |
| Form DEFA14A PRECISION BIOSCIENCES | SEC filing · Form DEFA14A | SEC EDGAR | +1.25% | -6.70% | |
| Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference | Press release | Business Wire | +1.25% | -6.70% | |
| Form PRE 14A PRECISION BIOSCIENCES For: May 21 | SEC filing · Form PRE | SEC EDGAR | -0.42% | -8.91% | |
| iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission | Press release | Business Wire | +0.29% | +2.18% | |
| Form 8-K PRECISION BIOSCIENCES For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | +9.13% | |
| Form 10-K PRECISION BIOSCIENCES For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.00% | +0.71% | |
| Form 8-K PRECISION BIOSCIENCES For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -4.00% | +0.71% | |
| Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update | Press release | Business Wire | -4.00% | +0.71% | |
| Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program | Press release | Business Wire | -0.47% | -5.07% | |
| Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 | Press release | Business Wire | +1.27% | +13.35% | |
| Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event | Press release | Business Wire | +6.72% | +2.17% | |
| Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 | Press release | Business Wire | +1.27% | +13.35% | |
| Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis | Press release | Business Wire | +2.47% | +6.91% | |
| Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference | Press release | Business Wire | -2.26% | -3.51% | |
| Form 8-K PRECISION BIOSCIENCES For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +1.83% | +6.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DTIL section they belong to.
Where else DTIL is measured.
DTIL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Precision BioSciences, Inc.'s median reaction calculated?
Every labeled DTIL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 394 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of DTIL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DTIL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.